Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-01-21
2000-11-28
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514468, 514471, 5142295, A61K 3144, A61K 3134, A61K 31535
Patent
active
061536202
ABSTRACT:
A method for modulating onset of tardive dyskinesia in a subject includes the step of administering to the subject an opiate receptor antagonist concomitantly with the neuroleptic. Also, a method for modulating a genetic or idiopathic or psychogenic hyperkinetic movement disorder, such as that characteristic of Huntington's Disease, includes the step of administering to the subject an opiate receptor antagonist.
REFERENCES:
Webster Dictionary p. 763, 1990.
Cadet et al. "Naltrexone Inhibits..." Neuropeptides 8(1) 87-91 (1986) Abstracted Chem Abs 105(17):146140 (1986).
D.R. Burt, I. Creese, S.H. Snyder, "Antischizophrenic Drugs: Chronic Treatment Elevates Dopamine Receptor Binding in Brain", Jul. 7, 1976, revised Oct. 6, 1976, Science vol. 196, pp. 326-328.
M.D. Hall, P. Jenner, C.D. Marsden, N.M.J. Rupniak, "Short Term Changes in Cerebral Dopamine Receptor Function During Continuous Haloperidol Administration", (1982) British Journal of Pharmacology, vol. 76 p. 233P.
P. Muller, P. Seeman, "Dopaminergic Supersensitivity After Neuroleptics; Time-Course and Specificity", Psychopharmacology 60. 1-11 (1978) pp. 1-11.
P. McGonigle, S. Boyson, S. Reuter, P. Molinoff, "Effects of Chronic Treatment with Selective and Nonselective Antagonists on the Subtypes of Dopamine Receptors", SYNAPSE 3:74-82 (1989) pp. 74-82.
C.A. Wilmot, A.M. Szczepanik, "Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain", Brain Research 487 (1989), pp. 288-298.
J.L. Waddington, A.J. Cross, S.J. Gamble, R.C. Bourne, "Spontaneous Orofacia Dyskinesia and Dopaminergic Function in Rats After 6 Months of Neuroleptic Treatment", Apr. 29, 1983, Science, vol. 220, pp. 530-532.
H.L. Klawans, Jr., R. Rubovits, "An Experimental Model of Tardive Dyskinesia", Journal of Neural Transmission (1972) pp. 235-246.
B. Weiss, S. Santelli, G. Lusnik, "Movement Disorders Induced in Monkeys by Chronic Haloperidol Treatment", Psychopharmacology, Received Feb. 10, 1976; Final Version Jan. 11, 1977; pp. 289-293.
D. Tarsy, R.J. Baldessarini, "Behavorial Supersensitivity to Apomorphine Following Chronic Treatment with Drugs Which Interfere with the Synaptic Function of Catecholamines", Neuropharmacology, 1974, pp. 927-940.
G. Ellison, P. Johansson, E. Levin, R. See, L. Gunne, "Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and the D2 agonist LY171555 on oral movements in rats", Psychopharmacology (1988), Received Jul. 14, 1987; Final version May. 10, 1988; pp. 253-257.
G. Ellison, R. See, "Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia", Psychopharmacology, Received Mar. 6, 1989; Final version Mar. 6, 1989, pp. 564-566.
J.G. Nutt, A.J. Rosin, T. Eisler, D.B. Caine, T.N. Chase, "Effect of an Opiate Antagonist on Movement Disorders", 1978 Arch. Neurol., vol. 35 pp. 810-811.
J.S. Schneider, "Role of the Basal Ganglia in a Chemically Induced Dykinesia in Rat", (1984) Experimental Neurology, vol. 84, pp. 524-532.
J.L. Cadet, T.L. Braun, "Naltrexone Inhibits the Persistent Spasmodic Dyskinesia Induced by Chronic Intraperitoneal Administration of Iminodipropionitrile (IDPN)", (1986) Neuropeptides, vol. 8, pp. 87-91.
J.P. Lindenmayer, E. Gardner, E. Goldberg, L.A. Opier, S.R. Kay, H.M. van Praag, M. Weiner, St. Zukin, "High-Dose Naloxone in Tardive Dyskinesia", (1988), Psychiatry Research, Vo. 26, pp. 19-28.
R. Sandyk, S.R. Snider, "Naloxone Treatment of L-Dopa-Induced Dyskinesias in Parkinson's Disease", (1986) American Journal of Psychiatry, vol. 143, p. 118.
J. Volavka, B. Anderson, G. Koz, "Naloxone and Naltrexone in Mental Illness and Tardive Dyskinesia", (1982), Annuals N.Y. Acad. Science, vol. 398, pp. 97-102.
Criares Theodore J.
Trustees of Boston University
LandOfFree
Opiate receptor antagonist modulates movement disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Opiate receptor antagonist modulates movement disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Opiate receptor antagonist modulates movement disorder will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1726092